Tegio Capsule is an oral antitumor drug, mainly for the treatment of unresectable locally advanced or metastatic gastric cancer and postoperative adjuvant chemotherapy. Its adverse reactions mainly include acute pancreatitis, disseminated intravascular coagulation and abnormal liver function. The drug is a prodrug, which needs to be transformed into fluorouracil in the body, thus exerting its role as an antimetabolite and interfering with the synthesis of DNA in tumor cells. The main treatment of Tegio capsule is mainly used for unresectable locally advanced or metastatic gastric cancer, breast cancer, colon cancer, pancreatic cancer and biliary tract cancer, etc. Postoperative adjuvant chemotherapy can also be used. The main adverse reactions of the drug are as follows. 1. Acute pancreatitis: when abdominal pain or elevated serum amylase occurs, acute pancreatitis may occur. 2. Dehydration: dehydration may result from severe diarrhea. 3. Severe enteritis: severe abdominal pain and diarrhea are present. 4. Interstitial pneumonia: symptoms such as cough, shortness of breath, dyspnea and fever. 5. Severe stomatitis, peptic ulcer, peptic bleeding and peptic perforation. 6. Disseminated intravascular coagulation. 7. severe liver function abnormalities such as fulminant hepatitis. 8. Acute renal failure. 9. Neuropsychiatric abnormalities such as cerebral leukoencephalopathy. 10. Bone marrow suppression, hemolytic anemia. 11. Rhabdomyolysis. It should be noted that a history of severe allergy to the components of the drug, severe myelosuppression, severe renal and hepatic function abnormalities, patients undergoing treatment with other fluorouracil antineoplastic drugs are prohibited, pregnant women are prohibited. The drug needs to be used under the guidance of a doctor, do not blindly use the drug on your own to avoid adverse consequences.